Finally, we provide the first evidence of the dysregulation of hepatic HTR2A and HTR2B mRNA abundance in women with MO and NAFLD, which could suggest a new therapeutic target. This evidence concerns the gene HTR2B and metabolic dysfunction-associated steatotic liver disease.